relative of Vioxx, which was linked to heart attacksKathleen Kerr, Newsday, Melville, N.Y.
Mar. 21, 2007 -- In a bid to recapture a piece of the arthritis pain-relief market, Merck & Co. is seeking government approval for Arcoxia, a chemical relative of Vioxx, the drug pulled off drugstore shelves in 2004 after being linked to heart attacks.
In its last full year on the market, Vioxx brought in about $2.5billion in sales. If the Food and Drug Administration approves Arcoxia, Merck could recoup some of those sales.
On April 12 an FDA advisory panel will consider approval of Arcoxia for osteoarthritis; it is already sold in 62 other countries. The FDA usually follows advisory panel recommendations. Continue reading ...
No comments:
Post a Comment